Erectile Dysfunction Drugs Market - Growth, Trends, and Forecast (2019 - 2024)
発行: Mordor Intelligence LLP
ページ情報: 英文 114 Pages
The major factors for the growth of the erectile dysfunction (ED) drugs market include the rising adoption of a sedentary lifestyle along with the associated stress, rising geriatric population, and comorbidity between erectile dysfunction and heart diseases, and diabetes.
Sedentary lifestyles, alcoholism, and smoking greatly increase the risk of erectile dysfunction. Increasing adoption of these poor lifestyle choices will lead to the overall growth of the erectile dysfunction drugs market. The rise in the number of ED cases can be correlated with the high growth of obesity, diabetes, and cardiovascular disorders. According to the World Health Organization, 17.7 million people died from cardiovascular diseases in 2015, representing 31% of all global deaths. Out of these deaths, 7.4 million deaths were due to coronary heart disease, ED could be an important marker for coronary artery disease (CAD). It has also been found that the onset of ED preceded the onset of CAD in almost 2/3 of the cases. Hypertension is also another major illness linked to erectile dysfunction and as reported by CDC in 2018, the prevalence of hypertension has grown at a considerable rate, to approximately 65 million people suffering from the condition in the US. The growing number of patients suffering from cardiovascular diseases is going to contribute to the rapidly growing pool of erectile dysfunction patients which in turn will lead to more patients seeking treatment hence boosting the overall growth of the market over the forecast period.
As per the scope of this report, erectile dysfunction is a very common condition and it can be defined as the inability to maintain an erection sufficient for sexual intercourse. The drugs used in the treatment of ED are covered under the scope of the report. The market is segmented by product type, distribution channel, and geography.
Retail Pharmacies is the Segment by Distribution Channel is expected to Dominate the Market
The retail pharmacies are expected to dominate the market owing to the easy availability of the erectile dysfunction drugs at retail stores. As per the data published by the Consumer Healthcare Products Association, there are more than 750,000 retail establishments in the US, both rural and urban consumers have access 24/7 to treatments for various conditions. Furthermore, several studies show that ED is increasingly prevalent with age and around 40% of men are affected at age 40. Thus, owing to the easy availability of the drug and rising cases of ED the market is expected to witness high growth over the forecast period.
North America is Expected to Dominate the Market
North America is expected to dominate the erectile dysfunction drugs market, owing to the rising geriatric population, increase in cases of ED and the presence of better healthcare infrastructure. According to the United States Census Bureau's Statistics as of 2017, the total number of people 65 and older exceeds 50 million, and between 2020-2030 the number of elderly is projected to increase by almost 18 million. Although much smaller in total size, the number of people aged 85 and older is expected to more than triple from an estimated 6 million today to nearly 20 million by 2060. The rise in geriatric population is expected to increase the number of patients suffering from ED, as it is very common in men above age 40. North America was followed by Europe in 2017. The availability of various ED drugs through over the counter (OTC) and online channels is a key factor for dominance of these regions. The presence of online pharmacy stores is a blessing in disguise for several patients who are conscious about visiting a retail pharmacy store to purchase ED and other sexual wellness products.
The market studied is a fragmented market owing to the presence of the various small and large market players. Some of the market players are Apricus Biosciences, Inc., Bayer AG, Eli Lilly and Company, Ferring Pharmaceuticals, GlaxoSmithKline plc., Metuchen Pharmaceuticals, LLC, Pfizer Inc., S.K. Chemicals Co. Ltd., Teva Pharmaceutical Industries Ltd., and VIVUS, Inc.